1. Market Research
  2. > Biotechnology Market Trends
  3. > Biotechnology Analysis & Statistics in Japan, February 2018 (p6)

Biotechnology Analysis & Statistics in Japan, February 2018 (p6)

151-180 of about 300 reports

Drug Analysis: Fasenra

Drug Analysis: Fasenra

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewFasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Drug Overview: Xolair

Drug Overview: Xolair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewXolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Dupixent

Drug Analysis: Dupixent

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewDupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug Overview: Dupixent

Drug Overview: Dupixent

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewDupixent (dupilumab; Regeneron/Sanofi) is an injectable monoclonal antibody directed against the interleukin (IL)-4 receptor alpha subunit, which blocks signaling from both IL-4 and IL-13. ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Fasenra

Drug Overview: Fasenra

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewFasenra (benralizumab; AstraZeneca/Kyowa Hakko Kirin) is a humanized monoclonal antibody which binds to the alpha chain of the interleukin (IL)-5 receptor on eosinophils and therefore depletes ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States, Japan, European Union
Drug Analysis: Xolair

Drug Analysis: Xolair

  • $ 10000
  • Industry report
  • February 2018

Drug OverviewXolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical, Chronic Disease
  • Countries : United States, Japan, European Union
AnGes MG Inc (4563) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AnGes MG Inc (4563) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • February 2018

SummaryAnGes MG Inc (AnGes) is a biopharmaceutical company which discovers and develops gene and nucleotide based drugs and reagents for use in functional analysis of genetic medication. The company specializes ...

  • Industries : Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan
Japan Molecular Diagnostics Market: Supplier Shares and Market Segment Sales Forecasts 2017-2022

Japan Molecular Diagnostics Market: Supplier Shares and Market Segment Sales Forecasts 2017-2022

  • $ 750
  • Industry report
  • January 2018

This report provides an overview of the Japanese molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.Table of ContentsBusiness E ...

  • Industries : Diagnostics
  • Countries : Japan
Drug Analysis: DCVAC/PCa

Drug Analysis: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: DCVAC/PCa

Drug Overview: DCVAC/PCa

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewDCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Mircera

Drug Analysis: Mircera

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewMircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The drug ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union, Europe
Drug Overview: Epogen

Drug Overview: Epogen

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewEpogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson&Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Epogen

Drug Analysis: Epogen

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewEpogen (epoetin alfa; Amgen/Kyowa Hakko Kirin/Johnson and Johnson) is an erythropoiesis-stimulating agent administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: NeoRecormon

Drug Analysis: NeoRecormon

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewNeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of ...

  • Industries : Medical Biotechnology
  • Countries : Japan, European Union
Drug Overview: NeoRecormon

Drug Overview: NeoRecormon

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewNeoRecormon (epoetin beta; Roche/Chugai) is an erythropoiesis-stimulating agent (ESA) administered by intravenous (IV) or subcutaneous (SC) injection, and is indicated for the treatment of ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan, European Union
Drug Overview: Aranesp

Drug Overview: Aranesp

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewAranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Overview: Mircera

Drug Overview: Mircera

  • $ 10000
  • Industry report
  • January 2018

Drug Overview Mircera (methoxy polyethylene glycol-epoetin beta; Roche/Vifor/Chugai) is a novel erythropoiesis-stimulating agent (ESA) designated as a continuous erythropoietin receptor activator. The ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union, Europe
Drug Analysis: Aranesp

Drug Analysis: Aranesp

  • $ 10000
  • Industry report
  • January 2018

Drug OverviewAranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Global Industrial Enzymes Industry

Global Industrial Enzymes Industry

  • $ 5600
  • Industry report
  • January 2018

This report analyzes the worldwide markets for Industrial Enzymes in US$ Thousand by the following Product Segments: Carbohydrases, Proteases, Lipases, and Others.The report also analyzes the following ...

  • Industries : Industrial Biotechnology
  • Countries : APAC, Japan, World, Europe, Latin America
Global Human Growth Hormone Drugs Industry

Global Human Growth Hormone Drugs Industry

  • $ 5450
  • Industry report
  • January 2018

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million.The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of ...

  • Industries : Medical Biotechnology
  • Countries : Europe, World, APAC, Japan, United States
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017

  • $ 2000
  • Company report
  • December 2017

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal ...

  • Industries : Pathology, Chronic Disease, Healthcare, Pharmaceutical, Medical Biotechnology
  • Countries : United States, Japan, World
Heart Transplant Rejection - Pipeline Review, H2 2017

Heart Transplant Rejection - Pipeline Review, H2 2017

  • $ 2000
  • Company report
  • December 2017

Heart Transplant Rejection - Pipeline Review, H2 2017SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection - Pipeline Review, H2 2017, ...

  • Industries : General Medicine and Specialty Medicine, Medical Biotechnology, Pharmaceutical, Biopharmaceutical, Biopharmaceutical, Healthcare, Therapy
  • Countries : World, Japan
Valneva SE – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Valneva SE – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • Company report
  • December 2017

Valneva SE – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportSummaryMarketline’s Valneva SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report ...

  • Industries : Pharmaceutical, Therapy, Medical Biotechnology
  • Countries : France, Japan
Crohn’s Disease: Treatment

Crohn’s Disease: Treatment

  • $ 3739
  • Industry report
  • December 2017

DescriptionDatamonitor Healthcare surveyed 240 gastroenterologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain insight into Crohn’s disease diagnosis, ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Pharmaceutical
  • Countries : United States, Japan, European Union
Drug analysis: Erbitux

Drug analysis: Erbitux

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Industries : Therapy, Medical Biotechnology
  • Countries : United States, Japan, European Union
Drug analysis: C-Cure

Drug analysis: C-Cure

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewC-Cure is a bone marrow-derived stem cell therapy aimed at regenerating cardiac tissue following severe damage due to myocardial infarctions. C-Cure consists of a patient’s own cells harvested ...

  • Industries : Medical Biotechnology, Chronic Disease, Biopharmaceutical, Biopharmaceutical, Pathology
  • Countries : United States, Japan, European Union
Drug analysis: Vectibix

Drug analysis: Vectibix

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewVectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents ...

  • Industries : Medical Biotechnology, Cancer, Therapy, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Drug Analysis: Multikine

Drug Analysis: Multikine

  • $ 10000
  • Industry report
  • December 2017

Drug OverviewMultikine is an investigational immunomodulator composed of a proprietary cocktail of naturally occurring cytokines such as interleukins, interferons, chemokines, and colony-stimulating factors. ...

  • Industries : Medical Biotechnology
  • Countries : United States, Japan, European Union
Asia-Pacific Genetic Testing Market Outlook to 2024

Asia-Pacific Genetic Testing Market Outlook to 2024

  • $ 5995
  • Industry report
  • December 2017

Asia-Pacific Genetic Testing Market Outlook to 2024SummaryGlobalData’s new report, Asia-Pacific Genetic Testing Market Outlook to 2024, provides key market data on the Asia-Pacific Genetic Testing market. ...

  • Industries : Diagnostics, Medical Biotechnology, Biotechnology, Healthcare
  • Countries : East Asia, APAC, China, World, Japan, United States, Australia
Drug Analysis: Mavenclad

Drug Analysis: Mavenclad

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewMavenclad contains cladribine, a small molecule that suppresses the immune system by selectively targeting lymphocytes, which are cells that seem to be major players in MS pathological mechanisms. ...

  • Industries : Medical Biotechnology
  • Countries : United States, European Union, Japan, Europe

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on